Interactions of Mouse Paneth Cell alpha -Defensins and alpha -Defensin Precursors with Membranes

PROSEGMENT INHIBITION OF PEPTIDE ASSOCIATION WITH BIOMIMETIC MEMBRANES*

Donald P. SatchellDagger §, Tanya Sheynis§||, Yoshinori ShirafujiDagger , Sofiya Kolusheva||, Andre J. OuelletteDagger **, and Raz Jelinek||DaggerDagger

From the Departments of Dagger  Pathology and ** Microbiology & Molecular Genetics, University of California College of Medicine, Irvine, California 92697-4800 and the || Department of Chemistry, Ben-Gurion University of the Negev, Beersheva, Israel 84105

Received for publication, November 27, 2002, and in revised form, January 29, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The bactericidal activity of mouse alpha -defensins (cryptdins) requires proteolytic activation of inactive precursors by matrix metalloproteinase-7 (matrilysin, EC 3.4.24.23, MMP-7a). To investigate mechanisms of cryptdin-4 (Crp4) peptide interactions with membrane bilayers and to determine whether MMP-7-mediated proteolysis activates the membrane disruptive activity of Crp4, associations of Crp4 and melittin with biomimetic lipid/polydiacetylene chromatic vesicles were characterized. The peptides differ in their sensitivity to vesicle lipid composition and their depth of bilayer penetration. Crp4 undergoes strong interfacial binding onto lipid bilayers with disruption of the bilayer head group region, unlike melittin, which inserts more deeply into the hydrophobic core of the bilayer. Colorimetric and tryptophan fluorescence studies showed that Crp4 insertion is favored by negatively charged phospholipids and that zwitterionic and Escherichia coli phospholipids promote stronger interfacial binding; melittin-membrane interactions were independent of either variable. In contrast to the membrane disruptive activity of Crp4, pro-Crp4 did not perturb vesicular membranes, consistent with the lack of bactericidal activity of the precursor, and incubation of Crp4 with prosegment in trans blocked Crp4 and G1W-Crp4 membrane interactions at concentrations that inhibit Crp4 bactericidal activity. CD measurements showed that Crp4 has an expected beta -sheet structure that is not evident in the pro-Crp4 CD trace or when Crp4 is incubated with prosegment, indicating that the beta -sheet signal is attenuated by proregion interactions or possibly disrupted by the prosegment. Collectively, the results suggest that the prosegment inhibits Crp4 bactericidal activity by blocking peptide-mediated perturbation of target cell membranes, a constraint that is relieved when MMP-7 cleaves the prosegment.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Antimicrobial peptides have been identified as components of innate immunity in every living organism investigated (1), and the mammalian alpha -defensins were among the first antimicrobial peptide families to be recognized and characterized (2, 3). alpha -Defensins are major constituents of both azurophilic granules in mammalian phagocytic leukocytes and secretory granules of mammalian Paneth cells, where they are termed cryptdins (Crps)1 in mice (4, 5). In contrast to alpha -defensins in cells of myeloid origin, which provide a nonoxidative means for killing microorganisms after phagocytosis (6), Paneth cell alpha -defensins are secreted to function in the extracellular compartment (7, 8). These cationic peptides with molecular masses of 3-4 kDa contain six cysteine residues that form a distinctive tridisulfide array to produce an amphipathic peptide, a feature that is essential for its microbicidal activity (6). In mouse Paneth cells, the production of mature bactericidal alpha -defensins requires proteolytic activation by matrix metalloproteinase-7 (9), a process that precedes secretion (10).

Human and rabbit neutrophil alpha -defensins are structurally and functionally distinct. Human alpha -defensin HNP-2 is a noncovalent dimer, but rabbit NP-1 is monomeric (11, 12). Dimeric HNP-2 forms stable multimeric pores after insertion into model membranes (13), and a pore model in which six HNP-2 dimers intercalate in the bilayer to form the 20 Å pore annulus has been proposed based on fluorescence leakage studies with large unilamellar vesicles (LUV) (14). In contrast, NP-1 does not induce stable multimeric pores, but evidence shows that this peptide permeabilizes LUV by creating large, short-lived defects in the model membrane (15). Thus, myeloid alpha -defensins from human and rabbit neutrophils achieve bacterial cell killing by highly distinctive membrane disruptive mechanisms. Preliminary findings show that Crp4 induces graded leakage of fluorophores from LUV, but the mechanisms by which individual Paneth cell alpha -defensins achieve microbial cell killing are unexplored. As HNP and NP comparisons reveal, the means by which Paneth cell alpha -defensins exert bactericidal effects cannot be extrapolated from existing literature or from a single model peptide.

In this work, the newly developed lipid/polydiacetylene (PDA) colorimetric vesicle assay combined with fluorescence and CD spectroscopies have been applied to characterizing Crp4 interaction and permeation of membranes. The lipid/PDA system consists of mixed vesicles composed of PDA interspersed with natural lipids, and the vesicles undergo blue-red transitions when induced by a variety of biological molecules that interact with the vesicular lipid components. The polymeric PDA matrix, which forms the scaffold of the mixed vesicles, accommodates the incorporation of varied lipid components while maintaining an overall sensitivity to membrane properties and processes. Analyses of PDA-based mixed vesicles have proven useful in studies of varied membrane-related processes, including peptide-membrane interactions (16, 17), membrane permeation by penetration enhancers (18), and biological recognition events occurring at membrane interfaces (19). In particular, this colorimetric assay has provided insights into mechanisms of membrane permeation, including the degree of interfacial disruption by peptides, the depth of peptide penetration into the lipid bilayer, and changes in membrane fluidity in response to peptide exposure (16, 17).2 Crp4 was chosen for this study, because this secreted peptide functions in the extracellular compartment (20, 21) and is the most bactericidal mouse Paneth cell alpha -defensin (4, 5, 22) and because the molecular and cellular details of Crp4 activation from inactive pro-Crp4 by MMP-7 proteolysis are known (10).3 Furthermore, Crp4 has a unique structure among the known alpha -defensins in that its polypeptide backbone contains a three-residue deletion in the loop formed by the Cys3-Cys5 disulfide bond (4, 5, 22).

In the studies reported here, interactions between model membranes and mouse Crp4 and its precursor have been analyzed spectroscopically and by colorimetric measurements on lipid/PDA mixed vesicles, and those interactions were correlated with the bactericidal activity of the peptide. The mechanisms of Crp4 membrane binding and permeation and the sensitivity of that binding to the composition of the lipid bilayer were evaluated in relation to melittin, a classic amphipathic alpha -helical peptide (23). Also, the lack of pro-Crp4 microbicidal activity and the inhibitory action of the precursor proregion on Crp4 bactericidal activity are consistent with the inability of pro-Crp4 and proregion-Crp4 mixtures to interact with these model membranes.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Phospholipids, including dimyristoylphosphatidylcholine (DMPC), dimyristoylphosphatidylglycerol (DMPG), and lipopolysacharides (LPS from Escherichia coli 055:B5) were purchased from Sigma-Aldrich). LPS was dialyzed sequentially against 1 mM EDTA for 24 h and against distilled water to remove excess divalent cations, which can cause lipid/PDA vesicles to precipitate. The diacetylenic monomer, 10,12-tricosadiynoic acid, was purchased from GFS Chemicals (Powell, OH), washed in chloroform, and filtered through a 0.45-µm filter prior to use. For commercially obtained peptides, melittin was purchased from Sigma-Aldrich, and the Crp1 proregion consisting of the following primary structure: DPIQNTDEET KTEEQPGEDD QAVSVSFGDP EGTSLQEES was synthesized by Quality Controlled Biochemicals, Inc. (Hopkinton, MA). The properties of the synthetic prosegment have been reported previously (10).

Lipid Extraction from Bacteria-- E. coli strain B/r H-266 was grown at 37 °C for 24 h in LB medium. The lipids were extracted from E. coli by resuspending deposited bacterial cells in 4 M NaCl and an equal volume of a 1:1 mixture of chloroform and methanol. After the mixture was shaken gently for 1 h and refrigerated overnight, the chloroform and aqueous phases were separated by centrifugation at 5000 × g for 15 min, and the aqueous methanol solution was re-extracted with chloroform. The combined chloroform extracts were concentrated by solvent evaporation, and the residual lipid-containing fraction was lyophilized. The lipids were stored at -20 °C.

Preparation of Recombinant Cryptdin-4 Peptides-- Recombinant Crp4, the G1W-Crp4 variant, and procryptdin-4 (pro-Crp4) were expressed in E. coli as N-terminal His6-tagged fusion proteins. DNA coding for the Crp4 peptide, corresponding to nucleotides 182-274 of mouse Crp4 cDNA (27), was amplified and cloned in-frame with the N-terminal His6 in the EcoRI/SalI sites of pET-28a (Novagen, Inc., Madison, WI). The Crp4 coding cDNA sequences were amplified using forward primer (ER1-Met-C4-F), 5'-GCGCG AATTC ATCGA GGGAA GGATG GGT TTGTT ATGCT ATTGT, paired with reverse primer (pMALCrp4-R), 5'-ATATA TGTCG ACTCA GCGAC AGCAG AGCGT GTACA ATAAA TG (18). A Trp for Gly substitution was made at Crp4 N terminus by pairing the common reverse primer (pMALCrp4-R) with forward primer (ER1-Met-G1W-F) 5'-ATATG AATTC ATGTGGTTGTTATGCTAT to prepare G1W-Crp4. To prepare recombinant pro-Crp4, a Met-coding trideoxynucleotide was incorporated 5' of codon 20 in the Crp4 precursor cDNA and cloned in pET-28a as above. For cloning pro-Crp4, forward primer pETPCr4-F (5'-GCGCG AATTC ATGGA TCCTA TCCAA AACAC A) was paired with reverse primer SLpMALCrp4R (5'-ATATA TGTCG ACTGT TCAGC GGCGG GGGCA GCAGT ACAA). The reactions were performed by incubating the reaction mixtures at 95 °C for 5 min, followed by successive cycles at 60 °C for 1 min, 72 °C for 1 min, and 94 °C for 1 min for 40 cycles. The underlined codon in each forward primer denotes a Met codon to incorporate a CNBr cleavage site immediately upstream of the designed peptide N terminus.

Recombinant proteins were expressed in E. coli BL21(DE3)-CodonPlus-RIL cells (Stratagene Cloning Systems, Inc., La Jolla, CA) transformed with appropriate cDNA constructs. The cells were grown at 37 °C to A620 = 0.9 in Terrific Broth medium consisting of 12 g of Bacto Tryptone (Becton Dickenson Microbiological Systems, Inc., Sparks, MD), 24 g of Bacto Yeast Extract (Becton Dickenson), 4 ml of glycerol, 900 ml of H2O, 100 ml of sterile phosphate buffer consisting of 0.17 M KH2PO4, 0.72 M K2HPO4, and 70 µg/ml kanamycin (28). Expression of fusion proteins was induced with 0.1 mM isopropyl-beta -D-1-thiogalactopyranoside, and bacterial cells were harvested by centrifugation and stored at -20 °C after growth at 37 °C for 6 h. The cells were lysed by resuspending bacterial cell pellets in 6 M guanidine HCl in 100 mM Tris-HCl, pH 8.1, followed by sonication at 70% power, 50% duty cycle for 2 min using a Branson Sonifier 450. The lysates were clarified by centrifugation in a Sorvall SA-600 rotor at 30,000 × g for 30 min at 4 °C prior to protein purification.

Purification of Recombinant Crp4 and pro-Crp4 Proteins-- His-tagged Crp4 fusion proteins were purified using nickel-nitrilotriacetic acid resin affinity chromatography by incubating cell lysates with nickel-nitrilotriacetic acid resin (Novagen, Madison, WI) at a ratio of 25:1 (v/v) in 6 M guanidine HCl, 20 mM Tris-HCl (pH 8.1) for 4 h at 4 °C. Fusion proteins were eluted with 2 column volumes of 6 M guanidine HCl, 1 M imidazole, 20 mM Tris-HCl (pH 6.4) dialyzed against 5% acetic acid (HOAc) in SpectraPor 3 dialysis membranes (Spectrum Laboratories, Inc., Rancho Dominguez, CA) and lyophilized. The Met residue introduced at the Crp4, G1W-Crp4, and pro-Crp4 N termini was subjected to CNBr cleavage by dissolving lyophilized His6 fusion proteins in 50% formic acid, addition of solid CNBr to 10 mg/ml final concentration, and incubation of the mixtures for 8 h in darkness at 25 °C. The cleavage reactions were terminated by addition of 10 vol of H2O, followed by freezing and lyophilization of the peptide mixture. The cleaved fusion peptide mixtures were dissolved in 5% acetic acid and stored at 4 °C.

Recombinant proteins were purified to homogeneity using reverse phase high performance liquid chromatography (RP-HPLC). After CNBr cleavage, Crp4, G1W-Crp4, and pro-Crp4 peptides were separated from CNBr fragments of the 36-amino acid His6 tag fusion partner by C-4 RP-HPLC on a Vydac 214TP1010 column (Vydac, Hesperia, CA). For Crp4, the samples were applied to C-4 columns in aqueous 0.1% trifluoroacetic acid, and the peptides were resolved with a 0-35% acetonitrile gradient developed over 55 min. All other peptides were purified to homogeneity by analytical C-18 RP-HPLC on a Vydac 218TP54 column. Using the same mobile phase, recombinant proteins were resolved with elution times ranging from 21 to 24 min using a 10-45% acetonitrile gradient over 55 min. Protein fractions containing Crp4 were identified by acid-urea PAGE as described (14) to confirm co-migration with natural Crp4 and pro-Crp4 and to evaluate the homogeneity of the preparation. Peptide concentrations were quantified by amino acid analysis (Waters Alliance, Bedford, MA) or UV absorption at 280 nm based on the extinction coefficients of the individual proteins. Molecular masses of purified peptides were determined using matrix-assisted laser desorption ionization mode mass spectrometry (Voyager-DE MALDI-TOF; PerkinElmer Life Sciences) in the UCI Biomedical Protein and Mass Spectrometry Resource Facility.

Bactericidal Peptide Assays-- Recombinant peptides were tested for microbicidal activity against E. coli ML35 and the PhoP- mutant of Salmonella typhimurium. Bacteria growing exponentially at 37 °C in trypticase soy broth were deposited by centrifugation at 1700 × g for 10 min, washed in 10 mM PIPES (pH 7.4) and resuspended in 10 mM PIPES (pH 7.4) that was supplemented with 0.01 vol of prepared trypticase soy broth. The peptide samples were lyophilized and dissolved in 10 mM PIPES (pH 7.4) at 1 mg/ml. The microorganisms were incubated at 37 °C with peptides in a total volume of 50 µl at a concentration of ~1 × 106/ml for 1 h in a shaking incubator. Following microbial exposure to peptides, 20-µl samples of peptide-exposed bacteria were diluted 1:200 with 10 mM PIPES (pH 7.4), and 50 µl of the diluted samples were plated on trypticase soy agar plates using an Autoplate 4000 (Spiral Biotech Inc., Bethesda, MD). The surviving microorganisms were counted as colony-forming units/ml after incubation at 37 °C for 12-18 h.

Vesicle Preparation-- Vesicles containing lipid components and PDA (DMPG/DMPC/PDA, 1:1:3 ratio; LPS/DMPC/PDA, 0.2:2:3 ratio) were prepared as follows. All of the lipid constituents were dissolved in chloroform/ethanol (1:1), dried together in vacuo to constant weight, and suspended in deionized water by probe sonication at 70 °C for 2-3 min. The vesicle suspension was cooled to room temperature, incubated overnight at 4 °C, and polymerized by irradiation at 254 nm for 10-20 s, resulting in solutions having an intense blue appearance.

Ultracentrifugation Binding Assay-- An ultracentrifugation binding assay was carried out for evaluation of peptide affinities, or partition coefficients, to the vesicles. First, a calibration graph that correlated peptide concentration with the absorbance at 220 nm was prepared and used to determine the concentration of soluble, unbound peptide. Varying quantities of peptides were added to aqueous lipid/PDA vesicle solutions containing 0.5 mM total lipid in 25 mM Tris-HCl (pH 8), and the solutions were incubated briefly at ambient temperature to allow equilibration of bound and unbound peptide species, followed by centrifugation at 30,000 rpm for 40 min in a SW-55 rotor to deposit vesicle-peptide aggregates. The concentration of soluble, i.e. unbound, peptide in the supernatant was determined by extrapolation from the calibration curve, and the quantity of bound peptide was calculated as the difference from the initial peptide concentration. The binding data results were confirmed using the Lowry method for determination of soluble peptide concentration (24).

UV-visible Measurements-- Spectral UV-visible measurements were carried out to analyze and quantify the colorimetric transitions undergone by the blue lipid/PDA vesicles. Peptides at concentrations ranging from 0.2 to 20 µM were added to 60-µl vesicle solutions consisting of 0.5 mM total lipid in 25 mM Tris-HCl (pH 8). Following addition of the peptides, the solutions were diluted to 1 ml, and spectra were acquired at 28 °C between 400 and 700 nm on a Jasco V-550 spectrophotometer (Jasco Corp., Tokyo), using a 1-cm optical path cell.

The extent of blue-to-red color transitions within the vesicle solutions, the colorimetric response (%CR), was defined and calculated as follows (19).
<UP>%CR = </UP>[(<UP>PB<SUB>0</SUB> − PB<SUB>1</SUB></UP>)<UP>/PB<SUB>0</SUB></UP>]<UP> × 100</UP> (Eq. 1)
where PB = Ablue/(Ablue + Ared), and A is the absorbance at 640 nm, the "blue" component of the spectrum, or at 500 nm, the "red" component. Note that blue and red refer to the visual appearance of the material, not actual absorbances. PB0 is the blue/red ratio of the control sample before induction of a color change, and PBI is the value obtained for the vesicle solution after the colorimetric transition occurred.

Fluorescence Measurements-- Changes in tryptophan intrinsic emission were measured for 10 µM peptide solutions titrated with vesicles. Fluorescence emission spectra were acquired at 28 °C on an FL920 spectrofluorimeter (Edinburgh Co., Edinburgh, UK), using excitation at 280 nm and emission at 345 nm. Excitation and emission slits were both 8 nm. Total sample volumes were 1 ml, and the solutions were placed in a quartz cell having a 0.5-cm optical path length. Light scattering from the vesicles was confirmed to account for less than 5% of the emission intensity.

Circular Dichroism-- CD spectra were acquired on an Aviv 62A-DS Circular Dichroism Spectrometer (Aviv Inc., Lakewood, NJ). Four scans were recorded between 190 and 250 nm with 1-nm acquisition steps. A 0.2-mm optical path length was used. All of the vesicle solutions had a total lipid concentration of 1 mM in 50 mM Tris-HCl at pH 8. The peptide concentrations were 0.1 mM.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Properties and Bactericidal Activities of Recombinant Crp4 and pro-Crp4 Peptides-- Consistent and efficient recombinant expression of Crp4, G1W-Crp4, and pro-Crp4 (Fig. 1A) was obtained using the pET-28 vector system. Recombinant His6-tagged fusion proteins were purified by affinity chromatography from the bacterial cell lysates ("Experimental Procedures"). After chemical cleavage with CNBr, Crp4, G1W-Crp4, and pro-Crp4 were purified to homogeneity by RP-HPLC ("Experimental Procedures"). Peptide homogeneity was evaluated using analytical RP-HPLC (not shown) and acid-urea PAGE (Fig. 1B). All of the purified peptides were homogeneous by these criteria, migrated as expected relative to native Crp4 and pro-Crp4 molecules (Fig. 1B),3 and the molecular masses of individual recombinant peptides determined by MALDI-TOF mass spectrometry matched the respective theoretical values exactly. Thus, the purified recombinant peptides were homogeneous and biochemically equivalent to the natural molecules.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 1.   Bactericidal activities of Crp4, pro-Crp4, and G1W-Crp4. A, the primary structures of recombinant peptides prepared and investigated in these studies. MMP-7 cleavage sites in the pro-Crp4 proregion, disclosed by protein sequencing of MMP-7 pro-Crp4 digests, are noted by downward arrows. Numerals below the pro-Crp4 sequence refer to residue positions at the beginning of N-terminal sequences detected in the digests, numbering with the initiating Met residue in prepro-Crp4 as residue position 1. The Crp4 and G1W-Crp4 peptide sequences are shown aligned with the Crp4 portion of pro-Crp4. In B, 1-µg samples of purified recombinant Crp4 (lane 1), G1W-Crp4 (lane 2), and pro-Crp4 (lane 3) were resolved by acid-urea PAGE and stained with Coomassie Blue (38). The arrows at left indicate, in descending order, the electrophoretic positions of pro-Crp4, Crp4, and G1W-Crp4. In C, exponentially growing bacterial cells were exposed to peptides at the indicated concentrations for 1 h, and the surviving bacteria were quantitated ("Experimental Procedures"). In both panels, the symbols denote surviving bacteria following exposure to pro-Crp4 (triangles), Crp4 (filled circles), or G1W-Crp4 (open circles). The upper panel shows killing curves against S. typhimurium PhoP-, and the lower panel shows killing of E. coli DH5alpha cells.

The in vitro microbicidal activities of Crp4, G1W-Crp4, and pro-Crp4 were evaluated against the defensin-sensitive PhoP- mutant of S. typhimurium and the DH5alpha strain of E. coli. As expected, Crp4 and G1W-Crp4 showed extensive bactericidal activity in the low micromolar range, equal to 5-10 µg/ml of peptide (Fig. 1C). The bactericidal activities of both peptides were the same against S. typhimurium PhoP- (Fig. 1C, upper panel). Against E. coli, the G1W-Crp4 variant was slightly less active, requiring 3-5-fold greater peptide concentrations to achieve killing equivalent to that of Crp4 (Fig. 1C, lower panel). In contrast to the bactericidal activities of these mature Crp4 peptides (5, 20, 22), pro-Crp4 lacked microbicidal activity (Fig. 1C). This finding is consistent with published (9, 10, 21) and recent3 studies showing that Crp precursors lack bactericidal activity until activated by cleavage with MMP-7. Because pro-Crp4 lacks bacterial cell killing activity, it provided a useful reagent for testing whether interactions with model membranes correlate with bactericidal activity. The bactericidal activity of G1W-Crp4 similarly validates the use of this peptide as a biologically relevant fluorescent probe (see below).

Melittin was selected as a model peptide for comparisons of bactericidal activity and membrane interactions with Crp4. The folded conformations of Crp4 and melittin differ. Crp4 is a typical alpha -defensin consisting of three beta -strands and no alpha -helical content. In contrast, melittin, is a potently bactericidal, membrane disruptive peptide that assumes an amphipathic alpha -helical structure in hydrophobic environments (23, 25). Interactions between melittin and model membranes have been studied extensively (26-30). Prior to comparisons of their membrane interaction dynamics, the bactericidal activities of Crp4 and melittin also were assayed against E. coli (Fig. 2). As anticipated, the bactericidal activity of melittin exceeds that of Crp4 against E. coli ML35, although both peptides are active in the low micromolar range (Fig. 2). The different antibacterial activities of these two peptides provide the biological basis for direct comparisons of the mechanisms by which these two molecules interact with model membranes.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   Relative bactericidal activities of Crp4 and melittin against E. coli. Exponentially growing E. coli ML35 cells were exposed to peptides at the concentrations shown in 10 mM PIPES (pH 7.4), 1% Trypticase Soy Broth for 1 h at 37 °C ("Experimental Procedures"). Following exposure, the bacteria were plated onto Trypticase Soy Agar plates, incubated for 16 h at 37 °C, and the surviving bacteria were quantitated as colony-forming units/ml (cfu/ml, "Experimental Procedures"). Colony-forming units/ml values below 1 × 103 indicate that no CFU were detected on the plate. Filled circles, Crp4; empty circles, melittin.

Colorimetric Analysis of Crp4-Membrane Interactions-- Previous studies of neutrophil alpha -defensin interactions with LUV composed of bacterial membrane phospholipids have correlated microbicidal activity with affinity for the membrane lipids (31). Accordingly, the binding and interactions of Crp4 with lipid bilayers were characterized using colorimetric lipid/PDA membrane assays and compared with the behavior of melittin. To first validate the colorimetric lipid/PDA assay for analysis of Crp4-membrane interactions, colorimetric titration curves were performed to test whether the blue-red transitions were dependent on peptide concentration and correlated with the phospholipid content in DMPC/PDA mixed vesicles (Fig. 3). The calculated %CR curves ("Experimental Procedures") within the vesicle solutions determined at different peptide concentrations showed that the extent of colorimetric transitions depend upon the DMPC/PDA ratio within the vesicles. In the presence of 1 µM Crp4, the %CR approached 80% when the DMPC/PDA molar ratio was 2:3, but lower %CR values of ~40 and ~20% were observed when the DMPC/PDA molar ratio of the mixed vesicles was reduced to 1:4 and 1:9, respectively (Fig. 3). These findings demonstrate that the observed chromatic transitions result from specific interactions between Crp4 and the phospholipid molecules incorporated into the PDA matrices and not from nonspecific associations of the peptide with the PDA polymeric matrix itself (17).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3.   Correlation between lipid content and concentration in Crp4-induced blue-red transitions. %CR values were calculated from measurements of chromatic shifts induced by Crp4 in DMPC/PDA vesicles ("Experimental Procedures"). The individual curves show %CR values for mixed vesicles prepared from the following proportions of DMPC to PDA. Circles, 10% DMPC/90% PDA; triangles, 20% DMPC/80% PDA; squares, 40% DMPC/60% PDA.

To evaluate the membrane association properties of Crp4 more completely, the relative peptide affinities of Crp4 and melittin for the lipid/PDA mixed vesicles were determined. The relative binding of melittin and Crp4 to vesicles was measured using an ultracentrifugation binding assay ("Experimental Procedures"), recording the partition coefficients of each peptide in the lipid/PDA vesicle environment (32). The binding assays showed that the initial linear slopes of Crp4 and melittin binding to vesicles in aqueous solutions are almost identical, yielding partition coefficients of ~0.9 for DMPC/PDA vesicles (Fig. 4A) and 0.75 for DMPG/DMPC/PDA vesicles (Fig. 4B). These results show that both peptides have similar affinities for lipid/PDA vesicles of different compositions (32). However, as evident from the plateaus corresponding to the quantities of each peptide bound at saturation, melittin and Crp4 differ extensively with respect to the maximal concentration of peptide bound to these model membranes. For example, both vesicle assemblies bound ~6 µM melittin at saturation (Fig. 4) but a maximum of only 1 µM Crp4. These findings suggest that the lower quantity of bound Crp4 results from incorporation of the peptide at the lipid/water interface (Fig. 4). In contrast, melittin adopts a helical amphipathic structure in hydrophobic membrane environments (23) and inserts deeply into lipid bilayer assemblies (33, 34), leading to accumulation of higher concentrations of membrane-associated melittin relative to levels of membrane-bound Crp4.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 4.   Relative binding of Crp4 and melittin to lipid/PDA vesicles. The slopes of individual curves are indicative of the relative affinities of Crp4 (triangles) and melittin (squares) for the lipid/PDA vesicles. Plateaus correspond to maximum concentration of bound peptides. A, vesicles composed of DMPC/PDA (2:3 mole ratio); B, vesicle composed of DMPG/DMPC/PDA (1:1:3 mole ratio).

Crp4 and melittin exhibit different membrane association profiles as well as differential sensitivities to phospholipid components of the vesicles. Generally, the bactericidal activity of antimicrobial peptides is consistent with the ability to penetrate and disrupt membranes (14). Fig. 5 depicts curves corresponding to the %CR induced by increasing quantities of bound peptides, i.e. the extent of induced blue-red transitions affected by the added peptides. Vesicles of three phospholipid compositions were investigated: DMPC/PDA at a 2:3 molar ratio (Fig. 5A), DMPG/DMPC/PDA at a 1:1:3 molar ratio (Fig. 5B), and vesicles using total cell lipids extracted from E. coli ("Experimental Procedures") at a 2:3 mass ratio of total lipid to PDA (Fig. 5C). The results in Fig. 5 show that %CR values correlate with the concentration of vesicle-bound peptide after accounting for the partition coefficients determined by ultracentrifugation binding assays (Fig. 4). Thus, the curves reveal that each peptide interacts with these membrane phospholipids differently, particularly with respect to the degree of penetration into the lipid layer.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5.   %CR transitions induced by Crp4 and melittin in vesicles of different lipid composition. Vesicle solutions containing DMPC/PDA (2:3 mole ratio, A), DMPG/DMPC/PDA (1:1:3 mole ratio, B), or total lipid extracts from E. coli (C) were exposed to Crp4 (triangles) or melittin (squares) as described under "Experimental Procedures." The relative increase in %CR is related to depth of peptide insertion into the lipid layer, showing that melittin inserts more deeply into the lipid bilayer.

Previously, the localization of peptide at the lipid bilayer surface was shown to induce a greater increase in %CR as a function of the quantity of bound peptide, and peptides that penetrate deeper into the hydrophobic core of the membrane bilayer produce a lower rise in chromatic shift (16). In principle, a direct relationship exists between higher %CR and interfacial lipid binding, because the mechanism of colorimetric transformation of the polymer assumes an increased mobility of the pendant side chains, induced through perturbations at the lipid/PDA vesicle surface (16, 17). In all three lipid systems, Crp4 gave rise to steeper increases in %CR than melittin at peptide concentrations <= 1 µM (Fig. 5). The Crp4 %CR values are 20-50% higher than those induced by melittin, an indication that Crp4 is located predominantly at the lipid/water interface, causing enhanced perturbation in the head group region of the lipid/polymer assembly (16). Melittin, on the other hand, inserted more deeply into the hydrophobic core of the lipid bilayer and consequently induced lower %CR values (Fig. 5). Previous colorimetric analyses have shown that melittin penetrates substantially into the hydrophobic acyl chain region in lipid/PDA vesicle assemblies (16). For example, a comparative study between melittin and a diastereomer analog that does not adopt helical structure and attach at the lipid/water interface has clearly shown a higher colorimetric response for the latter melittin analog relative to the native peptide (16).

The interactions of Crp4 and melittin with the biomimetic membrane system exhibit differential sensitivity to mixed vesicle lipid composition (Fig. 6). The experiments summarized in Fig. 6 were designed to investigate the specificity of the peptides to different membrane models, i.e. bacterial versus eukaryotic membranes. For example, the bilayer interactions evident from the %CR curves induced by Crp4 diverge markedly for vesicles of differing lipid compositions (Fig. 6A). In contrast, melittin interactions are almost superimposable, regardless of vesicle composition used in these experiments (Fig. 6B). The steepest %CR curve was induced by Crp4 in LPS-containing DMPC/PDA vesicles (60%CR at 0.5 µM Crp4), but 0.5 µM Crp4 induced only ~40%CR in DMPC/PDA vesicles (Fig. 6A). Interestingly, Crp4 inserted deeper into the lipid bilayer when the lipid/PDA matrix included DMPG or E. coli total lipids as shown by the respective 20 and 10%CR values in the presence of 0.5 µM Crp4 (Fig. 6A). Also, the increase in %CR as a function of Crp4 concentration was lower by almost one-half for DMPG or E. coli total lipid-containing vesicles. In contrast to these pronounced effects of lipid composition upon Crp4 bilayer penetration, interactions between melittin and vesicles were indistinguishable, regardless of vesicular phospholipid content (Fig. 6B). These results are likely to result from the high overall attraction of melittin to negatively charged membrane surfaces (PDA head groups are ionized with basic pH conditions). At peptide concentrations identical to those for Crp4, melittin elicited respective 4-6-fold lower %CR values for DMPC/PDA and DMPG/DMPC/PDA vesicles, indicating deeper insertion by melittin.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6.   Differential sensitivity of Crp4 and melittin interactions to vesicle lipid composition. The degree of blue-red transitions (%CR) induced by Crp4 (A) and melittin (B) were measured in mixed vesicles of differing lipid compositions. open circles, LPS/DMPC/PDA (0.2:2:3 mole ratio); squares, DMPC/PDA (2:3); triangles, DMPG/DMPC/PDA (1:1:3); filled circles, E. coli lipids/PDA (2:3 weight ratio). Crp4-lipid interactions are sensitive to the composition of the bilayer, but the %CR values for melittin are affected less by the vesicle lipid contents examined.

Tryptophan Fluorescence Measurements-- The incorporation of Crp4 into lipid/PDA vesicles was confirmed further by Trp fluorescence measurements and comparisons with melittin. The intrinsic fluorescence emission of the Trp indole ring is sensitive to the hydrophobicity of the local environment of the side chain (35, 36). Because peptides insert more deeply into the acyl core of the lipid bilayer, the environment of the Trp residue becomes more hydrophobic (35), shifting the fluorescence emission peak to higher wavelengths over the course of peptide-membrane associations. To perform these studies, the G1W-Crp4 analog was prepared with a Trp for Gly substitution at the peptide N terminus ("Experimental Procedures" and Fig. 1B). G1W-Crp4 is bactericidal (Fig. 1C) and exhibits lipid binding and colorimetric properties that are very similar to those of Crp4 (data not shown), evidence that the G1W replacement at the Crp4 N terminus does not alter the membrane disruptive properties of the peptide substantially. The native melittin primary structure contains a single Trp residue at position 19, which has been used extensively as a fluorescent probe for investigating melittin-membrane interactions (35, 36).

The observed shifts in the Trp fluorescence peaks resulting from G1W-Crp4 and melittin interactions with DMPC/PDA and DMPG/DMPC/PDA vesicles are summarized in Fig. 7. When G1W-Crp4 interacts with DMPG/DMPC/PDA vesicles, the Trp fluorescence emission signal shifted 15 nm, from 355 to 340 nm, at a lipid to peptide ratio of 10:1 (Fig. 7, upper panel). A smaller 10-nm fluorescence shift, from 352 to 342 nm, was observed for DMPC/PDA vesicles (Fig. 7, upper panel). Consistent with the colorimetric data (Fig. 5B), G1W-Crp4 inserts more deeply into the lipid moiety of the DMPG/DMPC/PDA assemblies relative to insertion into DMPC/PDA vesicles (Fig. 7, upper panel). Also consistent with the colorimetric measurements (Fig. 5B), the emission shifts produced by melittin were similar whether interacting with DMPG/DMPC/PDA or DMPC/PDA vesicles (Fig. 7, lower panel), showing that melittin was incorporated into vesicles to the same extent regardless of the lipid composition. As further evidence that melittin inserts into the lipid bilayers more deeply than G1W-Crp4, melittin shifted the Trp emission peak more than G1W-Crp4 regardless of the phospholipid composition of the vesicles (Fig. 7, lower panel).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7.   Trp fluorescence emission shifts of peptides in different vesicles. Trp fluorescence emission shifts induced by G1W-Crp4 (A) and melittin (B) were measured in DMPG/DMPC/PDA vesicles (1:1:3 mole ratio, triangles) and DMPC/PDA vesicles (2:3 mole ratio, squares). The fluorescence shifts correlate with greater depth of melittin incorporation within the hydrophobic environment of the lipid acyl chains.

Crp4 Precursor Does Not Perturb Lipid/PDA Vesicles-- Consistent with its lack of bactericidal activity (Fig. 1C), pro-Crp4 did not interact with lipid/PDA model membranes. Mouse cryptdins are processed from inactive pro-Crp precursors by MMP-7-mediated proteolysis (10), which is essential for the activation of bactericidal mature alpha -defensin peptides (10).3 To determine whether the lack of pro-Crp4 bactericidal activity correlates with an inability of the precursor to perturb membranes, interactions between pro-Crp4 and Crp4 with lipid/PDA vesicles were compared using DMPG/DMPC/PDA vesicles and found to be markedly different (Fig. 8A). In contrast to the ~50%CR induced by mature Crp4, pro-Crp4 induced a value of <5%CR, evidence that interactions between pro-Crp4 and lipid/PDA assemblies were negligible. These findings are consistent with preliminary studies of Crp4 and pro-Crp4-induced graded fluorophore leakage from palmitoyl-oleoyl-phosphatidyl glycerol LUV.4


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 8.   Attenuation of Crp4-membrane interactions by proregion. In A, %CR measurements of interactions between 1.3 µM Crp4 and pro-Crp4 and vesicles composed of DMPC/PDA (2:3 mole ratio) were taken ("Experimental Procedures"). In B, the %CR values represent the interactions between Crp4 and Crp4 prosegment mixtures at several Crp4 to proregion molar ratios. In C, Trp emission shifts were measured for G1W-Crp4 and for G1W-Crp4 prosegment mixtures at the indicated molar ratios. Colorimetric and Trp fluorescence measurements demonstrate that pro-Crp4 associates poorly with membranes and that the Crp prosegment prevents of membrane interactions of when added to mature Crp4 in trans.

Prosegment Inhibits Crp4 Lipid/PDA Vesicle Interactions-- Soluble, intact prosegments inhibit the in vitro bactericidal activity of mature alpha -defensins from human neutrophils (37) and mouse Paneth cells (10). Accordingly, the effects of added prosegment on Crp4 membrane interactions were evaluated. The addition of increasing quantities of full-length Crp1 prosegment to Crp4 prior to mixing with the lipid/PDA vesicles ("Experimental Procedures") inhibited the Crp4-induced %CR to low levels similar to those induced by pro-Crp4 (Fig. 8B). Prosegment alone induced no %CR (data not shown). The extent to which the colorimetric response was blocked related directly to the molar ratio of prosegment to Crp4 in the mixtures. At the highest Crp4:prosegment ratio tested (11:1), the %CR recorded was nearly 40%, similar to the 48% CR value obtained with intact Crp4 alone (Fig. 8B). At increasingly higher prosegment to Crp4 molar ratios, %CR diminished progressively to a nadir of 5% at a Crp4/prosegment ratio of 0.6 (Fig. 8B).

Addition of the Crp1 proregion in trans exhibited similar inhibitory effects on G1W-Crp4 interactions with membrane vesicles as measured by shifts in Trp fluorescence emission. As shown in Fig. 8C, the prosegment blocked G1W-Crp4 incorporation into the lipid moieties, consistent with inhibition of %CR by the proregion (Fig. 8B). Compared with the 10-nm Trp emission peak shift recorded for G1W-Crp4, a peak shift of only 1 nm was recorded for G1W-Crp4 when preincubated with prosegment at 0.6 mol of G1W-Crp4/mol of prosegment, concentrations that inhibit Crp4 bactericidal activity (10). Again, prosegment alone did not alter Trp fluorescence emission (data not shown). This negligible Trp shift supports the conclusion that G1W-Crp4 associations with the lipid bilayer are blocked or minimized in the presence of equimolar or greater concentrations of intact proregion. However, at Crp4 to proregion molar ratios of 4:1, the ~8-nm shift in Trp fluorescence approached that of G1W-Crp4 alone. These findings support a model in which the proregion association with Crp4, possibly through charge neutralization at specific residue positions, inhibits peptide bactericidal activity by interfering with peptide-membrane interactions.

Analyses of CD spectra were consistent with the interpretation of the preceding membrane perturbation experiments and provided insights into the structural properties of native Crp4, its inactive Crp4 precursor, and Crp4 in the presence of inhibitory concentrations of Crp1 prosegment (Fig. 9). In aqueous solutions of DMPC/PDA, native Crp4 exhibits a characteristic beta -sheet CD spectrum (Fig. 9, solid line). On the other hand, the CD spectra for both pro-Crp4 (Fig. 9, short dashes) and Crp4-prosegment mixtures at 0.6:1 molar ratios differ and are indicative of random coil peptide conformations (Fig. 9, short and long dashes, respectively). These CD signatures show that the beta -sheet trace is attenuated in pro-Crp4 and in the noncovalent Crp4-prosegment complex. This was particularly evident when prosegment was added in trans and when the CD trace represents the difference spectrum obtained after the prosegment CD trace was subtracted (Fig. 9, long dashed tracing), depicting primarily the Crp4 signature. These data suggest that one possible mechanism for prosegment inhibition of Crp bactericidal activity involves destabilization or attenuation of the beta -sheet topology, perhaps via electrostatic interactions that disrupt the ability of the Crp4 molecule to perturb target cell membranes.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 9.   Destabilization of Crp4 structure by the proregion. CD data spectra indicate that the beta -sheet structure of native Crp4 is attenuated in pro-Crp4 and after addition of prosegment to Crp4 in trans. CD traces were recorded in aqueous solutions containing DMPC/PDA vesicles (2:3 mole ratio, "Experimental Procedures"). Solid line, mature Crp4; long dashes, pro-Crp4; short dashes, Crp4 combined with equimolar ratio of prosegment.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Prosegment proteolysis during MMP-7-mediated pro-Crp processing results in activation of cryptdin bactericidal activity from inactive proforms.3 The underlying biophysical effects of the prosegment upon the Crp4 sequence, however, are not known. The results of the colorimetric and spectroscopic analyses presented here support the conclusion that the pro-Crp4 proregion maintains the Crp4 peptide in an inactive state by inhibiting interactions between Crp4 and lipid bilayers (Fig. 8). Consistent with this notion, similar molecular mechanisms appear to operate when prosegment, added in trans, prevents membrane association between vesicles and the mature Crp4 peptide. Of course, caution should be exercised in extrapolating from these in vitro studies to the factors that may be associated with killing mechanisms in vivo. Recent findings show that MMP-7 activation of pro-Crp4 is independent of proteolysis at two sites within the proregion,3 but the detailed molecular mechanisms by which MMP-7 cleavage eliminates the inhibitory effects of the prosegment remain to be elucidated. The experimental approaches described here appear to provide the level of sensitivity and selectivity required for defining those mechanisms.

Crp4 membrane interactions are sensitive to the phospholipid constituents of the lipid bilayer component in the PDA mixed vesicles. These findings are consistent with the ability of rabbit alpha -defensins to permeabilize LUV being dependent on vesicle lipid composition (31) and with studies of Crp4-induced fluorophore leakage from LUV prepared from palmitoyl-oleoyl-phosphatidyl glycerol or LUV made from 4:1 palmitoyl-oleoyl-phosphatidyl glycerol:palmitoyl-oleoyl-phosphatidyl choline.4 For example, spectroscopic data (Fig. 7) showed that the depth of Crp4 insertion is favored by the presence of negatively charged phospholipids in the lipid bilayer and that zwitterionic phospholipids and LPS promote greater interfacial binding. Colorimetric and Trp fluorescence results are consistent in indicating deep penetration of Crp4 into PDA vesicles consisting of E. coli total cell lipids (Figs. 5 and 6). This finding is somewhat unexpected because LPS is an integral component of Gram-negative bacterial cell envelope, although it seems unlikely that the complex orientation and organization of the membrane-associated LPS is retained in the E. coli lipids/PDA vesicle environment.

The apparent interfacial lipid binding and perturbation of Crp4 in the biomimetic model membrane suggests that Crp4 associates and permeates the membrane bilayer by mechanisms that are distinct from those of melittin. Moreover, the bactericidal and membrane permeation differences between Crp4 and melittin are most likely consequences of the distinctly different structural and functional properties of the two peptides. Comparisons of the colorimetric transitions induced in lipid/PDA vesicles incorporating different lipid/PDA ratios (Fig. 3) confirmed that the chromatic transformations correspond to specific interactions between the peptides and the lipid components incorporated within the PDA matrices. The colorimetric and Trp fluorescence experiments are consistent with a model indicating that Crp4 undergoes interfacial binding onto lipid bilayers with disruption of the bilayer head group region. Furthermore, Crp4 interactions at the lipid/water interface are more pronounced than those induced by melittin, which inserts more deeply into the hydrophobic core of the vesicles. The interfacial binding of Crp4, the absence of significant peptide insertion into the bilayer, and the apparent dependence of peptide-membrane interactions on vesicle lipid composition suggest that Crp4 cytolytic mechanism(s) differ from those of linear amphipathic peptides that adopt helical conformations to facilitate lipid bilayer penetration. In particular, models such as the barrel-stave (39) or carpet mechanism (40, 41) are not consistent with our results and not adequate to explain the membrane permeation properties of Crp4.

Colorimetric analysis demonstrates that Crp4-membrane association, characterized extensively in Figs. 3-7, is attenuated by the prosegment and that this effect depends on the prosegment to Crp4 ratio (Fig. 8). Measurements of Trp fluorescence spectra independently showed that prosegment also inhibited G1W-Crp4 insertion into lipid bilayers when the peptide was incubated with prosegment before mixing with vesicles (Fig. 8). Furthermore, CD experiments provided evidence that the beta -sheet structure of Crp4 is attenuated in both pro-Crp4 or when prosegment was added to Crp4 in trans (Fig. 9). Although the individual residues that associate to cause the inhibition are not known, it seems likely that the 13 anionic side chains of the proregion interact with and neutralize the seven cationic side chains on the Crp4 peptide surface, thus inhibiting electrostatic interactions at the target cell membrane. Collectively, these findings are consistent with a model in which MMP-7 cleavage of the pro-Crp4 proregion allows Crp4 to assume a tertiary conformation that permits the peptide to associate with and disrupt target cell membranes, thus activating bactericidal peptide activity.

    ACKNOWLEDGEMENTS

We thank Dr. Michael E. Selsted for useful discussions, Dr. Agnes Henschen-Edman (UCI Biomedical Protein and Mass Spectrometry Resource Facility) for peptide sequencing and analysis of recombinant peptides, and Khoa Nguyen, Vungie Hoang, and Victoria Rojo for excellent technical assistance.

    FOOTNOTES

* This work was supported by funds from the Israel-United States Binational Science Foundation (to R. J. and A. J. O.) and by National Institutes of Health Grants DK10184 (to D. P. S.) and DK44632 (to A. J. O.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally to these studies.

Present address: Biocides R&D, The Dow Chemical Company, Buffalo Grove, IL 60089.

Dagger Dagger Member of the Ilse Katz Center for Nanoscience and Technology. To whom correspondence should be addressed: Dept. of Chemistry, Ben-Gurion University of the Negev, Beersheva, Israel 84105. Tel.: 972-8-6461747; Fax: 972-8-6472943; E-mail: razj@bgumail.bgu.ac.il.

Published, JBC Papers in Press, February 6, 2003, DOI 10.1074/jbc.M212115200

2 M. Katz, H. Tsubery, M. Fridkin, S. Kolusheva, and R. Jelinek, submitted.

3 Shirafuji, Y., Tanabe, H., Satchell, D. P., Henschen-Edman, A., Wilson, C. L., and Ouellette, A. J. (2003) J. Biol. Chem. 278, 7910-7919.

4 J. Cummings, D. P. Satchell, T. K. Vanderlick, and A. J. Ouellette, unpublished observation.

    ABBREVIATIONS

The abbreviations used are: Crp, cryptdin; LUV, large unilamellar vesicle(s); PDA, polydiacetylene; DMPC, dimyristoylphosphatidylcholine; DMPG, dimyristoylphosphatidylglycerol; LPS, lipopolysaccharide; pro-Crp, procryptdin-4; RP-HPLC, reverse phase high performance liquid chromatography; MALDI-TOF, matrix-assisted laser desorption ionization mode time-of-flight; PIPES, 1,4-piperazinediethanesulfonic acid; %CR, percentage colorimetric response.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Zasloff, M. (2002) Nature 415, 389-395[CrossRef][Medline] [Order article via Infotrieve]
2. Lehrer, R. I., Selsted, M. E., Szklarek, D., and Fleischmann, J. (1983) Infect Immun. 42, 10-14[Medline] [Order article via Infotrieve]
3. Selsted, M. E., Brown, D. M., DeLange, R. J., and Lehrer, R. I. (1983) J. Biol. Chem. 258, 14485-14489[Abstract/Free Full Text]
4. Selsted, M. E., Miller, S. I., Henschen, A. H., and Ouellette, A. J. (1992) J. Cell Biol. 118, 929-936[Abstract]
5. Ouellette, A. J., Hsieh, M. M., Nosek, M. T., Cano-Gauci, D. F., Huttner, K. M., Buick, R. N., and Selsted, M. E. (1994) Infect Immun. 62, 5040-5047[Abstract]
6. Lehrer, R. I., and Ganz, T. (2002) Curr. Opin. Immunol. 14, 96-102[CrossRef][Medline] [Order article via Infotrieve]
7. Ouellette, A. J., and Bevins, C. L. (2001) Inflamm. Bowel Dis. 7, 43-50[Medline] [Order article via Infotrieve]
8. Ouellette, A. J., and Selsted, M. E. (1996) FASEB J. 10, 1280-1289[Abstract/Free Full Text]
9. Wilson, C. L., Ouellette, A. J., Satchell, D. P., Ayabe, T., Lopez-Boado, Y. S., Stratman, J. L., Hultgren, S. J., Matrisian, L. M., and Parks, W. C. (1999) Science 286, 113-117[Abstract/Free Full Text]
10. Ayabe, T., Satchell, D. P., Pesendorfer, P., Tanabe, H., Wilson, C. L., Hagen, S. J., and Ouellette, A. J. (2002) J. Biol. Chem. 277, 5219-5228[Abstract/Free Full Text]
11. Hill, C. P., Yee, J., Selsted, M. E., and Eisenberg, D. (1991) Science 251, 1481-1485[Medline] [Order article via Infotrieve]
12. Pardi, A., Zhang, X. L., Selsted, M. E., Skalicky, J. J., and Yip, P. F. (1992) Biochemistry 31, 11357-11364[Medline] [Order article via Infotrieve]
13. Wimley, W. C., Selsted, M. E., and White, S. H. (1994) Protein Sci. 3, 1362-1373[Abstract/Free Full Text]
14. White, S. H., Wimley, W. C., and Selsted, M. E. (1995) Curr. Opin. Struct. Biol. 5, 521-527[CrossRef][Medline] [Order article via Infotrieve]
15. Hristova, K., Selsted, M. E., and White, S. H. (1996) Biochemistry 35, 11888-11894[CrossRef][Medline] [Order article via Infotrieve]
16. Kolusheva, S., Shahal, T., and Jelinek, R. (2000) Biochemistry 39, 15851-15859[CrossRef][Medline] [Order article via Infotrieve]
17. Kolusheva, S., Boyer, L., and Jelinek, R. (2000) Nat. Biotechnol. 18, 225-227[CrossRef][Medline] [Order article via Infotrieve]
18. Evrard, D., Touitou, E., Kolusheva, S., Fishov, Y., and Jelinek, R. (2001) Pharm. Res. 18, 943-949[CrossRef][Medline] [Order article via Infotrieve]
19. Kolusheva, S., Kafri, R., Katz, M., and Jelinek, R. (2001) J. Am. Chem. Soc. 123, 417-422[CrossRef][Medline] [Order article via Infotrieve]
20. Ouellette, A. J., Satchell, D. P., Hsieh, M. M., Hagen, S. J., and Selsted, M. E. (2000) J. Biol. Chem. 275, 33969-33973[Abstract/Free Full Text]
21. Ayabe, T., Satchell, D. P., Wilson, C. L., Parks, W. C., Selsted, M. E., and Ouellette, A. J. (2000) Nat. Immunol. 1, 113-118[CrossRef][Medline] [Order article via Infotrieve]
22. Ouellette, A. J., Darmoul, D., Tran, D., Huttner, K. M., Yuan, J., and Selsted, M. E. (1999) Infect. Immun. 67, 6643-6651[Abstract/Free Full Text]
23. Smith, R., Separovic, F., Milne, T. J., Whittaker, A., Bennett, F. M., Cornell, B. A., and Makriannis, A. (1994) J. Mol. Biol. 241, 456-466[CrossRef][Medline] [Order article via Infotrieve]
24. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275[Free Full Text]
25. Dempsey, C. E. (1990) Biochim. Biophys. Acta 1031, 143-165[Medline] [Order article via Infotrieve]
26. Ladokhin, A. S., and White, S. H. (2001) Biochim. Biophys. Acta 1514, 253-260[Medline] [Order article via Infotrieve]
27. Ladokhin, S., M. E., and White, S. H. (1997) Biophys. J. 72, 1762-1766[Abstract]
28. Hristova, K., Dempsey, C. E., and White, S. H. (2001) Biophys. J. 80, 801-811[Abstract/Free Full Text]
29. Blondelle, S. E., and Houghten, R. A. (1991) Biochemistry 30, 4671-4678[Medline] [Order article via Infotrieve]
30. Shai, Y. (1999) Biochim. Biophys. Acta 1462, 55-70[Medline] [Order article via Infotrieve]
31. Hristova, K., Selsted, M. E., and White, S. H. (1997) J. Biol. Chem. 272, 24224-24233[Abstract/Free Full Text]
32. White, S. H., Wimley, W. C., Ladokhin, A. S., and Hristova, K. (1998) Methods Enzymol. 295, 62-87[CrossRef][Medline] [Order article via Infotrieve]
33. Brauner, J. W., Mendelson, R., and Prendergast, F. G. (1987) Biochemistry 26, 8151-8158[Medline] [Order article via Infotrieve]
34. Frey, S., and Tamm, L. K. (1991) Biophys. J. 60, 922-930[Abstract]
35. Dufourcq, J., and Faucon, J. F. (1977) Biochim. Biophys. Acta 467, 1-11[Medline] [Order article via Infotrieve]
36. Batenburg, A. M., hibeln, J. C., and de Kruijff, B. (1987) Biochim. Biophys. Acta 903, 155-165[Medline] [Order article via Infotrieve]
37. Valore, E. V., Martin, E., Harwig, S. S., and Ganz, T. (1996) J. Clin. Invest. 97, 1624-1629[Abstract/Free Full Text]
38. Selsted, M. E. (1993) in Genetic Engineering: Principles and Methods (Setlow, J. K., ed) , pp. 131-147, Plenum Press, New York
39. Ojcius, D. M., and Young, J. D. E. (1991) Trends Biochem. Sci. 16, 225-229[Medline] [Order article via Infotrieve]
40. Gazit, E., Boman, A., Boman, H. G., and Shai, Y. (1995) Biochemistry 34, 11479-11488[Medline] [Order article via Infotrieve]
41. Gazit, E., and Shai, Y. (1995) J. Biol. Chem. 270, 2571-2578[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.